R&G PharmaStudies Co. Ltd. A (301333) — Cash Flow-to-Debt Ratio
R&G PharmaStudies Co. Ltd. A (301333) has a Cash Flow-to-Debt Ratio of 0.16x as of June 2022, meaning its operating cash flow of CN¥40.98 Million could theoretically repay 0% of its total liabilities (CN¥264.39 Million) in one year. See R&G PharmaStudies Co. Ltd. A free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
R&G PharmaStudies Co. Ltd. A Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for R&G PharmaStudies Co. Ltd. A across 7 annual periods. Also explore 301333 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for R&G PharmaStudies Co. Ltd. A (2019–2025)
Year-by-year debt coverage analysis for R&G PharmaStudies Co. Ltd. A. For market capitalisation and broader financial context, see 301333 market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.27x | CN¥114.20 Million | CN¥423.89 Million | ▼ -12.9% |
| 2024 | 0.31x | CN¥154.76 Million | CN¥500.09 Million | ▼ -48.7% |
| 2023 | 0.60x | CN¥192.56 Million | CN¥319.17 Million | ▲ +33.8% |
| 2022 | 0.45x | CN¥130.47 Million | CN¥289.35 Million | ▼ -5.7% |
| 2021 | 0.48x | CN¥114.57 Million | CN¥239.66 Million | ▲ +116.1% |
| 2020 | 0.22x | CN¥44.10 Million | CN¥199.38 Million | ▼ -57.9% |
| 2019 | 0.52x | CN¥103.48 Million | CN¥197.12 Million | — |